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 Abstract 
  Background/Aims:   Behavioural and psychological symptoms of dementia (BPSD) in Alzhei-
mer’s disease (AD) greatly increase caregiver burden. The abilities of donepezil and memantine 
to manage BPSD within their licensed indications in AD were compared.   Methods:   A system-
atic review, random effects meta-analysis and Bucher indirect comparison were conducted. 
  Results:  Six randomised controlled studies (4 donepezil and 2 memantine) reported use within 
the licensed indication and had Neuropsychiatric Inventory (NPI) data suitable for meta-analy-
sis. BPSD showed significant improvement with donepezil compared with placebo [weighted 
mean difference (WMD) in NPI –3.51, 95% confidence interval (CI) –5.75, –1.27], whereas this was 
not the case for memantine (WMD –1.65, 95% CI –4.78, 1.49). WMD in NPI for donepezil versus 
memantine favoured donepezil but was not statistically significant (–1.86, 95% CI –5.71, 1.99;
p = 0.34).   Conclusion:   Within its licensed indication, donepezil is efficacious for the manage-
ment of BPSD in AD compared with placebo.    Copyright © 2011 S. Karger AG, Basel 
  Published online: July 20, 2011 
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 Introduction 
  Alzheimer’s disease (AD) is an incurable, neurodegenerative disease and is the most 
common cause of dementia. The non-cognitive, heterogeneous group of symptoms and be-
haviours occurring in people with dementia are termed behavioural and psychological 
symptoms of dementia (BPSD). These include severe mood changes, apathy, agitation, ag-
gression, anxiety, depression and delusions   [1]  . AD is one of the most economically costly 
diseases to society, and a large proportion of this cost is the long-term care provided by health 
professionals and institutionalisation of patients in the severe disease stages   [2]  .
    Although BPSD are not included as core features in the definition of the dementia syn-
drome, about 66% of people with dementia will experience some BPSD at any one time point, 
and for 33% of community-dwelling people with dementia the level of BPSD will be in the 
clinically significant range   [1, 3, 4]  . For people with dementia who are in institutional care, 
the figure for clinically significant BPSD rises to almost 80%   [5]  .
    As home care is usually preferred by patients and families, the range of behavioural dis-
turbances is an important risk factor for increasing caregiver burden and psychological dis-
tress   [6, 7]  . BPSD are also a strong predictor for institutionalisation of patients with demen-
tia   [8–10] .
    The traditional pharmacological management of BPSD (typical and atypical antipsy-
chotics) has significant morbidity, including extrapyramidal signs and symptoms, gait ab-
normalities, sedation, an increased risk of falls and fractures, increased incidence of deliri-
um, cerebrovascular adverse events and death   [11, 12]  .
    A treatment specifically for AD that is able to manage BPSD with an acceptable side ef-
fect profile is therefore highly desirable. Currently, cholinesterase inhibitors (ChEIs) are the 
standard of care for the treatment of cognitive deficits in patients with AD   [13]   and have 
fewer serious side effects than antipsychotics   [12]  .
    There is meta-analysis evidence that ChEIs as a class have a statistically significant ben-
efit compared with placebo in treating symptoms of BPSD in patients with AD   [14]  . In par-
ticular, donepezil (licensed for the symptomatic treatment of mild to moderately severe AD), 
which contributed the majority of studies to this analysis (6 of 10 studies), was found to have 
a statistically significant benefit compared with placebo when analysed separately   [14]  .
    Memantine is a moderate-affinity, uncompetitive antagonist of N-methyl-  D -aspartate 
receptors, which is approved for the treatment of moderate to severe AD. There are data to 
suggest that, in addition to its benefits on cognition, function and global status, memantine 
may also help alleviate behavioural symptoms   [15]  . A meta-analysis and 2 pooled analyses 
indicate that memantine confers benefit in the treatment of agitation and aggression over 
3–6 months in patients with AD   [12, 16, 17]  .
    However, to date no comparison has been made between donepezil and memantine to 
assess the relative efficacy of these two treatments, within their AD-licensed indications, for 
managing BPSD. 
    The current systematic review and meta-analysis of double-blind, placebo-controlled, 
randomised controlled trials (RCTs) were conducted to elucidate the efficacy of donepezil 
and memantine in managing BPSD in AD within their respective licensed indications and 
to compare their relative efficacy via an indirect comparison. 214
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  M e t h o d s  
  Systematic Literature Search 
  Reports of double-blind, placebo-controlled RCTs of donepezil and/or memantine ver-
sus placebo were identified by searches of the following electronic databases (conducted on 
February 19, 2010): 
    •  The Cochrane Library, incorporating 
  – the Central Register of Controlled Trials,
    – the Cochrane Database of Systematic Reviews,
    – the Database of Abstracts of Reviews of Effects and
    – the Health Technology Assessment Database;
    •  OVID MEDLINE in process; 
  •  OVID MEDLINE, 1950 to present day, and 
  •  OVID EMBASE, 1980 to present day. 
  There was no restriction on language of publication. The search strategy included both 
free text and MeSH terms for AD and the interventions of interest. In addition to electronic 
databases, the following conference proceedings were searched for the period 2005–2010:
    •  International Conference on Alzheimer’s Disease; 
  •  European Federation of Neurological Societies Congress, and 
  •  European College of Neuropsychopharmacology Congress. 
  Hand-searching was also performed by review of the bibliographies of included RCTs.
    The full list of criteria for eligible studies is reported in   table 1  . The inclusion and exclu-
sion criteria were examined initially against the title and abstract of articles identified by the 
literature search. The full text of potentially eligible articles was then checked to confirm 
eligibility. This stage of the review was conducted in duplicate, with any discrepancies re-
solved through consensus.
    The methodological quality of RCTs was assessed according to methods recommended 
in section six of the Cochrane Reviewer’s handbook (version 5.0.2)  [18]  independently by two 
reviewers. The likelihood of bias according to three components was assessed: adequacy of 
randomisation and allocation concealment procedures, adequacy of blinding procedures 
and completeness of follow-up. 
    Data were extracted from eligible publications by a reviewer into an Excel    spreadsheet. 
A second reviewer checked the resulting extraction and any discrepancies were resolved 
through discussion. 
    Data of interest to be extracted from the studies meeting the review inclusion criteria 
included the stage of AD as measured by the Mini Mental State Examination (MMSE) score, 
setting (community, out-patient, assisted living and/or nursing home), total Neuropsychiat-
ric Inventory (NPI) and MMSE scores at baseline, sample size in each treatment group, treat-
ment and dose/schedule, concomitant medications and duration of study. 
  Meta-Analysis  Methodology 
  In the meta-analysis, the outcome measure used was absolute change in NPI score com-
pared with baseline NPI score based on a last-observation-carried-forward (LOCF) analysis 
since this was reported consistently across all included studies. Outcome measures at the 24-
week time point were used in the analysis where available. The inclusion criteria allowed for 
the inclusion of outcomes measured between 3 months and 1 year from baseline (as per the 
meta-analysis by Campbell et al.   [14]   in 2008).
  The meta-analysis evaluated a pooled estimate of the weighted mean difference (WMD) 
in the change in NPI score between treatment arms. A random-effect meta-analysis was used 
to allow the true treatment effect to vary between studies due to heterogeneity. 215
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    The meta-analysis was conducted in Stata IC (version 10.1) using the   metan   package 
SJ9_2: sbe24_3   [19, 20]  .
    Adjusted indirect comparisons between donepezil and memantine (via the common 
comparator of placebo) were made using the method of Bucher et al.   [21]   to compare the 
WMD in NPI pooled across donepezil trials and the WMD in NPI pooled across memantine 
Table 1.   Inclusion and exclusion criteria
Criteria Included Excluded
Population Age: ≥18 years
Race: any
Qualifying disease: AD (diagnosed with established 
criteria, e.g. DSM-IV and NINCDS-ADRDA)
Any severity of disease at baseline
Community-/nursing home-dwelling resident
Age: ≤18 years
Perspective 
of the study
Prospective (concurrent)
Comparative
Retrospective 
(non-concurrent, historical)
Type of the study RCT (open label or blinded)
Cross-over trials with a wash-out period between 
treatments
Non-randomised CCT:
Cohort
Observational
Case control
Cross sectional
Non-comparative study
Language All None
Study duration Any None
Sample size Any None
Interventions/
treatments
Any dose of:
– Donepezil (Aricept)
– Memantine (Ebixa)
Control 
intervention/
treatments
Placebo/usual care
Any of the above interventions
Included study
outcomes
Global or individual BPSD using a validated 
assessment instrument, i.e. 
– NPI
– NPI-NH
– CMAI
– Apathy Scale
– BEHAVE-AD
– CERAD Behavioural Scale 
– CSDD
Efficacy only
Safety/tolerability
D  SM-IV = Diagnostic and Statistical Manual of Mental Disorders; NINCDS-ADRDA = National In-
stitute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related 
Disorders Association; CCT = controlled clinical trial; NPI-NH = NPI-Nursing Home Version; CMAI = 
Cohen-Mansfield Agitation Inventory; BEHAVE-AD = Behavioural Pathologic Rating Scale for Alzhei-
mer’s Disease; CERAD = Consortium to Establish a Registry in AD; CSDD = Cornell Scale for Depression 
in Dementia.216
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trials. This is, effectively, a meta-analysis stratified by drug intervention, and the method is 
advantageous because it maintains the randomisation as originally allocated. 
  Assessment  of  Bias 
  As per good meta-analysis practice, a formal assessment of publication bias was con-
ducted by plotting a funnel plot with the Egger linear regression test of asymmetry   [22, 23]  .
  R e s u l t s  
  Systematic Literature Search Results 
  Following removal of obvious duplicates, a total of 4,739 potentially relevant publica-
tions were identified for inclusion in the clinical systematic review, of which 4,561 were ex-
cluded on the basis of title and abstract (  fig. 1  ). On re-application of the review inclusion 
criteria to the 178 full-text papers, a further 155 were excluded. Therefore, 23 publications 
detailing 17 RCTs met the inclusion criteria and were included in the systematic review   [24–
46]   (donepezil: 15 publications of 11 placebo-controlled RCTs, and memantine: 8 publica-
tions of 6 placebo-controlled RCTs). This included 4 memantine monotherapy RCTs  [38–40, 
  Fig. 1.   Flow chart of inclusions/exclusions  .217
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44]   and 2 RCTs where patients stabilised on concomitant ChEIs were administered meman-
tine or placebo as add-on therapy   [27, 36]  .
    Following data extraction, 2 RCTs were excluded on the basis of non-availability of NPI 
outcome data suitable for meta-analysis   [24, 35]  . One study   [34]   was excluded because of 
methodological quality concerns: this donepezil-versus-placebo study in 566 community-
based subjects, with baseline MMSE 19, was excluded because less than one fifth of the 
planned subjects (n = 3,000) were in fact randomised (n   !   600) and attrition in the 1st year 
was 40%. These and further methodological concerns have been documented previously 
 [47] .
    Therefore, 14 trials were considered for inclusion in the meta-analysis. However, only 6 
trials (2 memantine   [40, 44]   and 4 donepezil   [29, 37, 42, 45]  ) were monotherapy trials with 
medication used within their licensed indication and were included in the licensed-indica-
tion meta-analysis. The  study by Gauthier et al.   [29]   (2002) was a substudy of that by Feld-
man et al.   [32]   (2001). The original publication   [32]   reported results from 290 subjects in a 
community-based or assisted-living setting and included patients with moderate to severe 
AD (MMSE 5–17). Donepezil is only licensed for use in patients with mild to moderately se-
vere AD (MMSE 10–26) and not in patients with severe AD (MMSE   !  10). The study by 
Gauthier et al.   [29]   reported exclusively on the patients with moderate AD within the trial, 
and results from this subgroup were included in the licensed indication meta-analysis.
    Description of RCTs Included in the Meta-Analysis 
  The baseline study characteristics of the 17 RCTs included in the systematic review are 
reported in   tables 2–4  . The 4 RCTs reporting results for donepezil used within its licensed 
indication in mild to moderately severe AD are described below:
    Gauthier et al.   [29]  : 207 participants recruited from 32 sites from Canada, Australia and 
France, assessed at 24 weeks, in the community or assisted-living setting, mean age 74 years, 
mean baseline behavioural disturbance NPI 18 points and MMSE     14, concomitant medi-
cation (psychotropics) permitted.
  Holmes et al.  [45] : 96 participants recruited from 16 sites in the UK, assessed at 24 weeks, 
presumed to be in the community although this was not stated specifically, mean age 79 
years, mean baseline NPI 14–15 points, MMSE     21, concomitant psychotropics permitted 
(39% donepezil group and 47% placebo group). The primary outcome was the change in NPI 
between week 12 (when randomisation occurred) and week 24.
  Johannsen et al.  [42] : 202 participants recruited from 57 sites in Belgium, Denmark, Ger-
many, Greece, Hungary, Iceland, The Netherlands, Poland and the USA, in the community 
or assisted-home-care setting, mean age 7 4 ( donepezil group ) and 71 years ( comparator 
group), mean baseline NPI not given, MMSE     19, concomitant psychotropics permitted 
(35% donepezil group and 39% comparator group). 
    Winblad et al.   [37]  : 286 participants recruited from 28 sites in Denmark, Finland, Nor-
way, Sweden and The Netherlands, assessed (primary) at 52 weeks, out-patients, mean age 
70 (donepezil group) and 60 years (placebo group), mean baseline NPI 12–13 points, MMSE 
    19, concomitant psychotropics permitted (32% donepezil group and 28% placebo group).
  Baseline characteristics for the 2 memantine monotherapy RCTs used within its licensed 
indication in moderate to severe AD are described below: 
    Reisberg et al.   [40]  : 252 participants recruited from 32 centres in the USA, in the com-
munity, mean age 76 years, mean baseline NPI 20–21 points, MMSE     8, certain concomi-
tant medications were excluded, including anticonvulsants, antiparkinsonian agents, hyp-
notic agents, anxiolytic agents and neuroleptic agents.218
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    van Dyck et al.   [44]  : 350 participants recruited from 35 sites in the USA, in own or rela-
tive’s home, mean age 78 years, mean baseline NPI 20 (memantine group) and 18 points (pla-
cebo group), MMSE 10, stable doses of antidepressants and antipsychotics permitted.
  Assessment  of  Bias 
  Figure 2  illustrates the funnel plot used to detect publication bias. In the absence of bias, 
the funnel plot will be symmetrical and data points should fall within the 95% confidence 
interval (CI) limits. The regression line in   figure 2   is fitted using the Egger linear regression 
test of asymmetry  [23] . If there is asymmetry, with smaller studies showing effects that differ 
systematically from larger studies, the regression line will not pass through the origin. The 
regression line intercept is a measure of the asymmetry whereby the larger the deviation 
from zero the greater the asymmetry.
  Although there is some asymmetry in the funnel plot indicating some potential for bias, 
funnel-plot asymmetry may also reflect other types of bias such as selection bias.
Table 2. Footnotes
NR = Not reported; SSRI = selective serotonin reuptake inhibitors.
a Inclusion criteria included MMSE score 1–10 and a Functional Assessment Staging rating of stage 5 (requires assistance 
in choosing proper clothing) to 7c (non-ambulatory/unable to walk without assistance).
b Most commonly used classes of drugs were analgesics, laxatives, hypnotics, sedatives and anxiolytics, diuretics, drugs 
used to treat anaemia, antidepressants, drugs to treat rheumatic diseases and gout, antibacterial agents, and antipsychotic 
drugs. More than 80% of patients were taking psychoactive medications [breakdown by class as follows: hypnotics, seda-
tives, and anxiolytics, 61% (donepezil, n = 78) vs. 58% (placebo, n = 70); antidepressants, 52% (n = 67) vs. 51% (n = 61); an-
tipsychotics, 38% (n = 48) vs. 42% (n = 50), respectively].
c 5 mg for the first 30 days followed by 10 mg thereafter (or 5 mg if not well tolerated). 
d p = 0.02 between groups.
e The majority of patients had an MMSE score of 6–12 (68.8% in the donepezil group and 68.3% in the placebo group).
f Clinician was permitted to reduce the study medication to 1 blinded tablet per day if necessary after week 6. The max-
imum dose of 10 mg/day was maintained by 85% of patients in the donepezil group at study endpoint.
g More than 20% of patients in either group were taking antiplatelet agents. The most common concomitant medications 
taken during the study (10% in either group) included acetylsalicylic acid, multivitamins, tocopherol, risperidone, para ceta-
mol, furosemide, levothyroxine sodium and ascorbic acid.
h Percentage taking at least one concomitant medication over the course of the study. Antihypertensive drugs were used 
more frequently in the placebo (24/144) than in the donepezil (14/142) group.
i Gauthier et al. [28] reported more elaborate results of NPI efficacy outcomes of the same patient population studied by 
Feldman et al. [32].
j 10 mg/day the intended dose: study medication could be reduced to 5 mg/day or placebo equivalent at any time during 
the study to improve tolerability.
k One patient with a baseline standardised MMSE score of 18 was randomised into the trial.
l Patients receiving psychotropic medications were generally required to have been on stable doses for at least 1 month 
before screening. Adjustments in psychotropic medication use were discouraged, but were permitted if clinically necessary. 
Most concomitant medications were allowed, except those with significant cholinomimetic or anticholinergic effects and 
investigational drugs; patients treated with tacrine must have discontinued use of the agent at least 30 days before the screen-
ing visit. 
m Stable doses of antidepressants (SSRIs) and low stable doses of atypical antipsychotics that were prescribed before 
study entry were allowed to be continued during the study. 
n MMSE 21–26 at baseline. 
o Placebo vs. donepezil 5 mg vs. donepezil 10 mg: psychotropics, 29.4 vs. 27.1 vs. 23.9%; cerebral circulation/metabolism 
enhancers, 9.8 vs. 9.4 vs. 9.8%; hypnotics, 20.6 vs. 11.5 vs. 18.5%; other, 37.3 vs. 32.3 vs. 41.3%.
p Open-label phase: 5 mg/day donepezil for 6 weeks followed by 10 mg/day for further 6 weeks. Patients were then ran-
domised to 10 mg/day donepezil for further 6 weeks after a 12-week open-label phase. If there was no marked cognitive 
decline (loss of >2 points on the MMSE compared with baseline) then randomised treatment continued for further 6 weeks.
q Treatment originally scheduled for 60 weeks (12-week run-in + 48-week maintenance treatment). However, following 
a protocol modification, there was an option to extend treatment indefinitely. [After a 6-week no-treatment washout, pa-
tients could continue with the same double-blind treatment that they had been receiving for 60 weeks for a further 48 weeks 
if they, their doctor and their carer judged that this course was appropriate. At the end of every 48-week treatment period, 
a further 4-week treatment-free washout took place, whereupon patients could once again continue with another 48-week 
phase of double-blind treatment.]
r Run-in treatment period of 12 weeks, in which patients were randomly allocated either to donepezil (5 mg/day) or pla-
cebo followed by a second randomisation to long-term donepezil (5 or 10 mg/day) or placebo.221
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  M e t a - A n a l y s i s  
  The analysis was subgrouped by disease severity (MMSE score at baseline) as per li-
censed indication (  fig. 3  ).
    For the licensed indication of donepezil (  fig. 3  , mild to moderate AD), a meta-analysis 
of 4 RCTs reported a statistically significant improvement in BPSD versus placebo as mea-
sured by NPI total score (WMD –3.51, 95% CI –5.75, –1.27; I  2   = 44.8%).
    In contrast, a meta-analysis of the 2 memantine monotherapy licensed-indication RCTs 
(  fig. 3  , moderate to severe AD) found no significant difference compared with placebo on 
NPI total score (WMD –1.65, 95% CI –4.78, 1.49; I  2   = 25.3%). For both results, the level of 
Table 3. M  ain study characteristics for published RCTs examining memantine monotherapy
First
author
MMSE
score
Setting Mean
age
years 
(SD)
Fe-
male
%
Mean
NPI 
score at 
baseline 
(SD)
Mean 
MMSE 
score at 
baseline 
(SD)
n Treatment/
dose
Con-
comitant 
medication
Study
duration 
weeks
Mild to moderate AD (n = 2)
Bakchine [38]
(2008) 
(full paper, 
12 European 
countries)
11–23
at baseline
Out-
patient
74.0 (7.4) 65 NA 18.6 (3.3) 318i Memantine 
(initial dose: 5 mg/day
then: 4!5 mg/day)h
Allowedc 24 
73.3 (6.9) 60 NA 18.9 (3.2) 152i Placebo 
(initial dose: 5 mg/day
then: 4!5 mg/day)h
Peskind [39]
(2006) 
(full paper, USA)
10–22
at screening/
baseline
Out-
patient
78.0 (7.3) 60 11.5 (13.2) 17.4 (3.7) 201 Memantine 
(initial dose: 5 mg/day
then: 4!5 mg/day)h
NR
24g
77.0 (8.2) 57 12.2 (13) 17.2 (3.4) 202 Placebo 
(initial dose: 5 mg/day
then: 4!5 mg/day)h
NR
Moderate to severe AD (n = 2)
Reisberg [40]
(2003) 
(full paper, USA)
3–14d
Resident 
in the 
community
75.5 (8.16) 72.2 21.4 7.8 (3.76) 126e Memantine (20 mg) Exclusions 
listedb
28 mean 
for both 
groups 24 
(SD 88)
75.8 (7.28) 65.5 19.5 8.1 (3.60) 126e Placebo (20 mg)
van Dyck [44] 
(2007) 
(full paper, USA)
5–14 
at screening/
baseline
Own or 
relative’s 
home
78.1 (8.2) 72.5 20.3 (15.7) 10.0 (2.8) 178 Memantine 
(initial dose: 5 mg/day
then: 4!5 mg/day)f
97.2%a
24g
78.3 (7.6) 70.3 17.5 (16.4) 10.3 (3.1) 172 Placebo 
(initial dose: 5 mg/day
then: 4!5 mg/day)f
97.1%a
a  The most common concomitant medications included acetylsalicylic acid, tocopherol, multivitamins and acetaminophen.
b Patients receiving the following concomitant medications were excluded: anticonvulsant agents, antiparkinsonian agents, hypnotic agents, 
anxiolytic agents, neuroleptic agents, cholinomimetic agents or any other investigational compounds.
c Selective serotonin reuptake inhibitors, oestrogens, anti-inflammatory drugs, -blockers, insulin and H2 blockers were allowed if dose and 
medication had been stable for at least 3 months and were kept stable during study; only non-opioid analgesics could be administered chroni-
cally; vitamin E, coenzyme Q and atypical antipsychotics were allowed if dose and medication had been stable for at least 30 days and kept stable 
during study; atypical antipsychotics were not to be taken 3 days before a visit.
d Stage 5 or 6 on the Global Deterioration Scale, and stage ≥6a on the Functional Assessment Staging instrument.
e Detailed patient information reported from only those completing the study: n = 97.
f Dose adjustments were permitted between weeks 3 and 8 for participants experiencing adverse events; however, participants unable to tol-
erate 20 mg/day by the end of week 8 were excluded from the study.
g A 1- to 2-week single-blind placebo run-in phase was completed before randomisation to assess compliance and to minimise treatment re-
sponse at baseline.
h Transient dose adjustments were permitted between weeks 3 and 8 for participants experiencing dose-limiting adverse events; however, all 
were required to receive the target dose of 20 mg/day by the end of week 8.
i The patients were randomised in a 2:1 ratio, to minimise patient exposure to placebo due to ethical considerations (availability of efficient 
symptomatic drugs for AD in the majority of countries).222
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variation in the treatment effects due to heterogeneity was considered acceptable, since I  2  
  6  50% is generally regarded to represent considerable or substantial heterogeneity requiring 
further exploration   [18]  .
  I n d i r e c t   C o m p a r i s o n  
  Based on the WMD in NPI shown in   figure 3  , an adjusted indirect comparison found 
that the WMD in NPI between donepezil and memantine was not statistically significant 
(–1.86; 95% CI –5.71, 1.99; p = 0.34).
  Discussion 
  Results from the present meta-analysis indicate that BPSD as measured by total NPI 
showed statistically significant improvement with donepezil monotherapy within its li-
censed indication (mild to moderately severe AD) compared with placebo (WMD –3.51, 95% 
CI –5.75, –1.27). In contrast, there was no statistically significant difference between meman-
tine monotherapy used per its license in moderate to severe AD and placebo (WMD –1.65, 
95% CI –4.78, 1.49). An indirect comparison numerically favoured donepezil versus meman-
tine, but the difference was not statistically significant (p = 0.34).
Table 4. M  ain study characteristics for published RCTs examining memantine as add-on therapy to stable donepezil/ChEI
First
author
Participants/
severity of 
disease
Setting Age 
years 
(SD)
Fe-
male 
%
NPI score 
at baseline 
(SD)
MMSE 
score at 
baseline 
(SD)
n Treatment/
dose
Concomitant medication Study
duration
weeks
Mild to moderate AD (n = 1)
Porsteinsson 
[36] (2008)
(full paper, 
USA) Patients 
had mild-
moderate 
ADi
Resident 
in the 
community
74.9
(7.64)
53.9 11.8 
(13.11)
16.7 
(3.67)
217 Memantine 
(initial dose: 
5 mg/day;
then: 
4!5 mg/day)a
Donepezil (n=154, 71.0%) 
9.5 81.5 mg/day
Rivastigmine (n=33, 15.2%) 
9.282.8 mg/day;
Galantamine (n=30, 13.8%)
24 
76
(8.43)
50.5 12.3
(13.28)
17.0 
(3.64)
216 Placebo 
(initial dose: 
5 mg/day;
then: 
4!5 mg/day)a
Donepezil (n=137, 63.4%) 
8.982.1 mg/day
Rivastigmine (n=44, 20.4%) 
10 82.6 mg/day
Galantamine (n=35, 16.2%)
Moderate to severe AD (n = 1)
Tariot [27]
(2004)
Cummings [26] 
(2006)d
van Dyck [25] 
(2006)d
(full paper, 
USA)
Patients had 
moderate-
severe ADa
Resident 
in the 
community
75.5 
(8.45)
63 13.4 
(SEM: 1.07)
9.9 
(3.13)
203 Memantine 
(week 1–4: 
5 mg/day;
week 5–24: 
4!5 mg/day)b
97.5%c
24 
75.5 
(8.73)
67 13.4 
(SEM: 1.08)
10.2 
(2.98)
201 Placebo 
(week 1–4: 
5 mg/day; 
week 5–24: 
4!5 mg/day)b
98%c
a  Dose adjustments were permitted between weeks 3–8 for participants experiencing adverse effects.
b All patients were to maintain stable donepezil therapy at entry dose as prescribed by the patient’s physician for the duration of the study.
c The most frequent medication classes (>20%) used during treatment with memantine were vitamins (77%), analgesics (48%), antidepressants 
(36%), mineral supplements (27%), lipid-reducing agents (25%), anxiolytics/neuroleptics (22%), and anti-inflammatory agents (24%).
d Cummings et al. [26] reported more in-depth results of NPI efficacy outcomes of the same patient population studied by Tariot et al. [27].223
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    The clinical relevance of a statistically significant WMD in total NPI score of –3.51 for 
donepezil is broadly in line with a change in NPI of 4 points, which is likely to confer a mod-
est clinical benefit   [48]  . However, there is still some debate as to what constitutes a clinically 
meaningful change in the NPI score, since a change measured by the scale is not always rep-
licated by a comprehensive assessment conducted by experienced clinical staff   [48]  . This is-
sue is exacerbated by the fact that BPSD is a complex cluster of signs and symptoms that 
  Fig. 2.   Funnel plot of mean dif-
ference (MD) in NPI score 
(LOCF) plotted against standard 
error. 
First author WMD NPI score (95% CI) Weight, %
Donepezil (mild to moderate AD)
Gauthier [29] (2002) –6.92 (–9.60, –2.24) 22.38
Holmes [45] (2004) –6.20 (–11.37, –1.03) 14.07
Johannsen [42] (2006) –2.87 (–6.28, –0.46) 34.27
Winblad [37] (2001) –1.13 (–4.01, 1.75) 29.26
Subtotal (I2 = 44.8%, p = 0.142) –3.51 (–6.75, –1.27) 100.00
Memantine (moderate to severe AD)
Reisberg [40] (2003) –3.30 (–7.22, 0.62) 48.28
van Dyck [44] (2007) –0.10 (–3.84, 3.64) 51.72
Subtotal (I2 = 25.3%, p = 0.247) –1.65 (–4.78, 1.49) 100.00
Overall (I2 = 35.6%, p = 0.170) –2.93 (–4.69, –1.17)
Weights are from random effect analysis
  Fig. 3.   Forest plot of random-effect meta-analysis for studies reporting use in licensed indication: done-
pezil, mild to moderately severe AD population, and memantine monotherapy, moderate to severe AD 
population. Note: ChEIs are also used in the placebo control arm; I  2   = Variation in effect attributable to 
heterogeneity. 
–11.4 0
Favours treatment Favours control
11.4224
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fluctuates over time. Nevertheless, evidence from the present meta-analysis suggests that 
within its licensed indication, donepezil may offer modest alleviation from BPSD, and given 
that it is generally well tolerated in this population   [47]  , it is an appropriate initial choice of 
pharmacotherapy for the management of these symptoms. 
    These data, focusing on licensed-indication use of donepezil and memantine, run con-
trary to the view that memantine may be effective for the management of BPSD  [49] . The cur-
rent review demonstrates that the evidence, within their respective licensed indications, is in 
fact stronger for donepezil. It is of interest to examine the licensed-indication results in the 
context of previous systematic reviews and meta-analyses. Of reviews supporting the use of 
memantine in BPSD, most relate to patients with moderate to severe   [15, 16, 50, 51]   or mod-
erately severe to severe AD   [17]  . Within the licensed indication of memantine, meta-analyses 
have found a statistically significant difference in total NPI versus placebo   [16, 50, 51]   or in 
the proportion of patients with improvement in neuropsychiatric cluster sub-items of the NPI 
(agitation/aggression, delusions or hallucinations)   [17]  . These meta-analyses of patients with 
moderate to severe AD (MMSE   !  20) or moderately severe to severe AD, respectively, have 
pooled trials where memantine was an add-on therapy (to a stable dose of donepezil or other 
ChEI)   [27, 36]  , with memantine monotherapy trials. The only 2 monotherapy trials of me-
mantine within its licensed indication that are used in these 5 reviews   [40, 44]  , as reiterated 
recently   [15]  , did not find a statistically significant difference in total NPI with memantine 
monotherapy versus placebo. Our results indicate that in spite of combining the data from 
these 2 trials, the effect of memantine on total NPI versus placebo remains statistically non-
significant.
  The Cochrane review of donepezil in dementia due to AD  [47]  reported that patients with 
mild-moderate AD benefited from donepezil treatment, including a reduction in behavioural 
disturbance. A later review   [14]   of all ChEIs (9 donepezil studies, 2 galantamine and 1 riv-
astigmine) reported a statistically significant effect on BPSD versus placebo in patients with 
mild to moderate AD but not among patients with moderate to severe AD. Our data lend fur-
ther support to these reviews’ conclusions, as related to donepezil in mild to moderate AD.
    The structured literature search including conference abstracts and the methodological 
quality of the included articles being assessed by two individuals separately contribute to the 
strength of evidence provided by this systematic review. Further, with the exception of study 
duration, which varied from 12 weeks to 1 year for donepezil studies, the licensed-indication 
meta-analysis involved broadly comparable RCTs.
    Regarding limitations, potential sources of residual reporting bias may stem from pub-
lication bias in that our search strategy reviewed only published data; unpublished data, grey 
literature (from the System for Information on Grey Literature in Europe) and ongoing stud-
ies were not sought. Some time lag bias may also have resulted from the search strategy in-
cluding conference proceedings from a relatively narrow time window, 2005–2010, which 
may have yielded positive findings but not yet given enough time for negative findings to be 
published, the latter being typically published with some degree of time lag compared with 
positive findings. 
    Our review was also limited by the small number of licensed-indication trials, particu-
larly for memantine monotherapy. The focus on total NPI was necessary as this was the most 
frequently reported outcome. Studies reporting BPSD outcomes as measured by other scales 
(e.g. the Behavioural Pathologic Rating Scale for Alzheimer’s Disease or Apathy Scale)   [24, 
35]  , or by individual NPI items or item clusters without total NPI were, therefore, not in-
cluded. Due to fundamental differences between the scales it was not possible to convert re-
sults to a comparable measure on the NPI scale. With regard to NPI subscales, data were not 
reported in a sufficient number of studies to make a meta-analysis feasible. 225
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    In summary, the present review contributes to rational health care decisions by present-
ing the current relative strength of evidence for the licensed use of donepezil or memantine 
in the management of BPSD. Donepezil monotherapy within its licensed indication is sig-
nificantly more efficacious than placebo for alleviating BPSD, whereas memantine mono-
therapy within its licensed indication has no statistically significant advantage over placebo 
in managing BPSD. An adjusted indirect comparison indicated a numerical but statistically 
non-significant trend favouring donepezil versus memantine in the management of BPSD. 
However, given that both treatments are licensed for different AD populations (donepezil for 
mild to moderately severe AD and memantine for moderate to severe AD), application of an 
indirect comparison, which in this case is necessarily based on the respective performance 
of each drug relative to a different AD population, may have limited value. 
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